237 related articles for article (PubMed ID: 11356940)
1. A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor.
Hammond-McKibben D; Lake P; Zhang J; Tart-Risher N; Hugo R; Weetall M
J Pharmacol Exp Ther; 2001 Jun; 297(3):1144-51. PubMed ID: 11356940
[TBL] [Abstract][Full Text] [Related]
2. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
3. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
4. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Sakagawa T; Kiyochi H; Honda K; Kobayashi N
Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.
Maeda A; Goto M; Zhang J; Bennet W; Groth CG; Korsgren O; Wennberg L
Transplantation; 2003 Apr; 75(8):1409-14. PubMed ID: 12717240
[TBL] [Abstract][Full Text] [Related]
6. FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.
Lima RS; Nogueira-Martins MF; Silva HT; Pestana JO; Bueno V
Transplant Proc; 2004 May; 36(4):1015-7. PubMed ID: 15194353
[TBL] [Abstract][Full Text] [Related]
7. A short course of cyclosporine immunosuppression inhibits rejection but not tolerance of rat liver allografts.
Huang WH; Yan Y; De Boer B; Bishop GA; House AK
Transplantation; 2003 Feb; 75(3):368-74. PubMed ID: 12589161
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
10. The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers.
del Rio ML; Pabst O; Ramirez P; Penuelas-Rivas G; Förster R; Rodriguez-Barbosa JI
Transpl Int; 2007 Oct; 20(10):895-903. PubMed ID: 17854447
[TBL] [Abstract][Full Text] [Related]
11. FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A.
Koshiba T; Van Damme B; Rutgeerts O; Waer M; Pirenne J
Transplantation; 2003 Apr; 75(7):945-52. PubMed ID: 12698078
[TBL] [Abstract][Full Text] [Related]
12. Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720.
Suzuki S; Li XK; Shinomiya T; Enosawa S; Kakefuda T; Mitsusada M; Amemiya H; Takahara S; Amari M; Naoe S; Hoshino Y; Chiba K
Transplant Proc; 1996 Aug; 28(4):2049-50. PubMed ID: 8769151
[No Abstract] [Full Text] [Related]
13. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice.
Matsumoto Y; Hof A; Baumlin Y; Hof RP
Transplantation; 2003 Oct; 76(8):1166-70. PubMed ID: 14578747
[TBL] [Abstract][Full Text] [Related]
15. FTY720 inhibits TH1-mediated allogeneic humoral immune response.
Peñuelas-Rivas G; Domínguez-Perles R; Brinkmann V; Del Rio ML; Muñoz-Luna A; Ramírez-Romero P; Parrilla-Paricio P; Rodríguez-Barbosa JI
Transplant Proc; 2005 Nov; 37(9):4124-6. PubMed ID: 16386642
[TBL] [Abstract][Full Text] [Related]
16. Suppression of acute and chronic cardiac allograft rejection in mice by inhibition of chemokine receptor 5 in combination with cyclosporine A.
Li J; Xia J; Zhang K; Xu L
J Surg Res; 2009 Nov; 157(1):81-90. PubMed ID: 19577762
[TBL] [Abstract][Full Text] [Related]
17. A new immunosuppressant, FTY720, in canine kidney transplantation: effect of single-drug, induction and combination treatments.
Suzuki T; Jin MB; Shimamura T; Yamashita K; Taniguchi M; Nomura M; Yokota R; Fukai M; Magata S; Horiuchi H; Fujita M; Nagashima K; Furukawa H; Todo S
Transpl Int; 2004 Nov; 17(10):574-84. PubMed ID: 15592714
[TBL] [Abstract][Full Text] [Related]
18. [Subrenal capsule assay using nude mice].
Kikuchi H; Asamura M; Gamoh M; Ohuchi H; Wakui A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):532-41. PubMed ID: 2321981
[TBL] [Abstract][Full Text] [Related]
19. Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.
Hsiao CC; Su WN; Forooghian F; Bader S; Rempel J; HayGlass KT; Gilman A; Schultz KR
Bone Marrow Transplant; 2002 Dec; 30(12):905-13. PubMed ID: 12476284
[TBL] [Abstract][Full Text] [Related]
20. Control of intestinal allograft rejection by FTY720 and costimulation blockade.
Yan S; Rodriguez-Barbosa JI; Pabst O; Beckmann JH; Brinkmann V; Förster R; Hoffmann MW
Transplant Proc; 2005; 37(1):114-5. PubMed ID: 15808565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
